Vascular Biogenics Ltd represents values of innovation, dedication, and patient-centricity. As a leading biopharmaceutical company, Vascular Biogenics is committed to developing transformative therapies for patients suffering from cancer and other severe diseases. The company's corporate philosophy revolves around pushing the boundaries of scientific knowledge to create groundbreaking treatments that improve patient outcomes and quality of life. With a strong focus on research and development, Vascular Biogenics aims to revolutionize the healthcare industry by harnessing the potential of gene therapy and targeted drug delivery. By prioritizing patient well-being and scientific excellence, Vascular Biogenics strives to make a meaningful impact on global healthcare.

Vascular Biogenics Ltd is primarily present in the United States, Israel, and various countries in Europe. With headquarters in Israel, the company operates its research and development facilities, clinical trials, and manufacturing operations in these regions. By focusing on innovative therapies for cancer and inflammatory diseases, Vascular Biogenics Ltd has established a significant presence in the global biopharmaceutical market.

Vascular Biogenics Ltd has achieved several significant milestones in its journey. One notable accomplishment is the successful completion of phase 2 clinical trials for its leading product candidate, VB-111. The company has also entered into strategic collaborations with renowned pharmaceutical companies, such as Bristol-Myers Squibb and Intrexon Corporation, to further develop and market its innovative therapies. In addition, Vascular Biogenics Ltd has received regulatory approvals for its clinical trials in various countries, including the United States and Europe. These milestones showcase the company's commitment to advancing novel treatments and highlight its potential for growth and success in the biotechnology industry.

Vascular Biogenics Ltd, also known as VBL Therapeutics, is a clinical-stage biopharmaceutical company based in Israel. Founded in 2000, the company is focused on the development of novel treatments for cancer and inflammatory diseases. VBL Therapeutics utilizes its proprietary technology platform, Vascular Targeting System (VTS), to design and develop therapies that target specific types of blood vessels associated with various diseases. The company's lead product candidate, VB-111, is being evaluated in multiple clinical trials for different cancer indications. Vascular Biogenics has a strong commitment to innovation and addressing unmet medical needs, positioning itself as a significant player in the pharmaceutical industry.

The main competitors of Vascular Biogenics Ltd in the market include prominent companies such as Genentech, Novartis, Merck & Co., Pfizer, and Johnson & Johnson.

Vascular Biogenics Ltd is primarily active in the biotechnology and pharmaceutical industries.

The business model of Vascular Biogenics Ltd (VBL) is focused on developing and commercializing gene-based therapies for various types of cancer. VBL utilizes its proprietary technology platform, known as Vascular Targeting System (VTS), to design and develop novel biologics that target and disrupt the blood vessels supplying nutrients to tumors. By inhibiting tumor blood flow, VBL's therapies aim to starve cancer cells and impede their growth, ultimately leading to tumor regression. VBL collaborates with leading academic institutions and pharmaceutical companies to conduct preclinical and clinical trials, evaluate safety and efficacy, and advance the development of potential cancer treatments.

De Vascular Biogenics K/W is -0,06.

De Vascular Biogenics KUV is 1,81.

De AlleAktien Kwaliteitsscore voor Vascular Biogenics is 6/10.

De verwachte Vascular Biogenics omzet is 1,96 mln. USD.

De verwachte Vascular Biogenics winst is -58,60 mln. USD.

Vascular Biogenics Ltd is an Israeli company specializing in the development of therapeutic products for the treatment of cancer and inflammatory diseases. The company focuses on the development of antibodies and peptides that can specifically block or activate molecules in the body. It collaborates with various partners for the discovery and development of new therapeutics. Its core product is an oncology product called VBG-8264, which is in the clinical stage of development. Another promising product in its portfolio is VascuGel, which aims to reduce inflammation and promote wound healing. The company utilizes various distribution channels and partnerships to market its products globally. Vascular Biogenics aims to improve the health of patients worldwide through its innovative products.

Vascular Biogenics keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Vascular Biogenics of het bedrijf keert geen dividend uit.

De ISIN van Vascular Biogenics is IL0011327454.

Het WKN van Vascular Biogenics is A119YE.

De ticker van Vascular Biogenics is VBLT.

Binnen de laatste 12 maanden betaalde Vascular Biogenics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Vascular Biogenics naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Vascular Biogenics is momenteel .

Vascular Biogenics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Vascular Biogenics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Vascular Biogenics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Vascular Biogenics van 10-8-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 10-8-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 10-8-2024.

In het jaar 2023 heeft Vascular Biogenics 0 USD aan dividenden uitgekeerd.

De dividenden van Vascular Biogenics worden in USD uitgekeerd.